Literature DB >> 34954702

En bloc resection for nonmuscle-invasive bladder cancer: selecting a proper laser.

Dmitry Enikeev1, Marek Babjuk2,3, Anastasia Shpikina1, Shahrokh Shariat1,2,3,4,5, Petr Glybochko1.   

Abstract

PURPOSE OF REVIEW: To discuss the most recent surgical lasers that have been made available to us and to evaluate their potential in performing en bloc resection of nonmuscle invasive bladder cancer. RECENT
FINDINGS: Laser en bloc resection of bladder tumors (ERBT) can be performed with a number of laser systems including Ho:YAG, GreenLight, diode, Tm:YAG and thulium fiber lasers (TFL). The data that is currently available suggests that the water-targeting devices (utilizing water as a primary chromophore - Ho:YAG, Tm:YAG, TFL) may have a number of advantages over hemoglobin-targeting systems (potassium titanyl phosphate:YAG, lithium triborate:YAG). One recent addition to the surgical armamentarium Moses effect enhanced Ho:YAG and the TFL (being able to work both in quasi-continuous and SuperPulsed modes) necessitates careful discussion and comparison with the other available devices.
SUMMARY: The majority of available lasers have proven to be safe to use and compared to electrocautery allow for lower rates of obturator nerve reflex and result in fewer bleeding complications. The minimal penetration depth and decreased peak power of Tm:YAG and TFLs render them the devices of choice when it comes to ERBT. Unfortunately, more studies on ERBT with TFL are needed in order for us to make a sound assessment of the respective pros and cons.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34954702     DOI: 10.1097/MOU.0000000000000968

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  1 in total

1.  En-bloc Laser Resection of Bladder Tumors: Where Are We Now?

Authors:  Massimiliano Creta; Giuseppe Celentano; Gianluigi Califano; Roberto La Rocca; Nicola Longo
Journal:  J Clin Med       Date:  2022-06-16       Impact factor: 4.964

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.